Crystagen

Recovery & Repair

🔧

Crystagen

Connective tissue bioregulator · Khavinson joint peptide · Cartilage bioregulator

Low EvidenceRecovery & Repair

A peptide bioregulator from the Khavinson Institute targeting connective tissue — cartilage, ligaments, and joints — for repair and age-related degeneration.

Half-Life

~30-60 minutes (estimated)

MW

N/A

Amino Acids

N/A

Evidence

Low Evidence

Regulatory Status

Research compound. Used in some Eastern European research and clinical settings for joint disease. Not FDA/EMA approved.

In Plain English

A short Russian-developed peptide that acts as an "on switch" for cartilage and connective tissue genes that get silenced with age or injury. Works at the gene level to restore collagen production and joint tissue health — complementary to BPC-157's healing approach.

Overview

Crystagen is a synthetic peptide bioregulator developed by the Khavinson research group at the St. Petersburg Institute of Bioregulation and Gerontology, specifically targeting connective tissue cells including chondrocytes, fibroblasts, and extracellular matrix-producing cells. It follows the same epigenetic bioregulator model as Epitalon and other Khavinson peptides — short peptides that bind chromatin and restore gene expression in aged or damaged tissue-specific cells. Research focuses on cartilage integrity, joint health, and connective tissue regeneration, making it relevant for osteoarthritis research and sports recovery applications.

Common Formats

  • Lyophilized powder (injectable)
  • Oral capsules (research)

Storage Notes

-20°C lyophilized. 4°C reconstituted. Protect from light and repeated freeze-thaw cycles.

Looking for multi-compound protocols?

Browse educational protocol discussions that include Crystagen.

Protocol Library

Related Compounds

Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.